Clinical characteristics of patients
| Age at diagnosis | TNM | Stage | Gleason score (biopsy) | Gleason score (surgery) | PSA (pre-treatment) | Clinical status at 1st vac | HLA typing | HER-2 status | Progression from 1st vac | |
|---|---|---|---|---|---|---|---|---|---|---|
| PR02 | 61 | G2T3bN0M0 | III | 6 (3 + 3) | 6 (3 + 3) | 12.6 | CS | A*24 A*32 DRB*07 DRBa15 | 1+ | NP |
| PR04 | 64 | G2T2bN0M0 | II | 5 (3 + 2) | 5 (3 + 2) | ---- | CS | A*02 DRB1*11 DRB1*16 | 1+ | NP |
| PR05 | 58 | G4T3bN x M1b | IV | 7 (3 + 4) | 7 (3 + 4) | 65 | CR/M | A*24 A*29 DRB1*11 DRB1*14 | 1+ | D (7) |
| PR06 | 61 | G3T4N1M1b | IV | 7 (4 + 3) | ---- | 92 | CS/M | A*02 A*02 DRB1*08 DRB1*11 | 1+ | CR (50) |
| PR08 | 51 | G2T4N1M0 | IV | 7 (4 + 3) | 7 (4 + 3) | 13.30 | CS/NM | A*24 A*68 DRB1*11 DRB1a14 | 1+ | CR (54)/NM |
| PR09 | 73 | G4T4N + M0 | IV | 4 (3 + 1) | 9 (5 + 4) | 12.3 | M | A*02 A*26 DRB1*16 DRB1*16 | 1+ | D (18) |
| PR10 | 52 | G2T3bN1M0 | III | 6 (3 + 3) | 7 (4 + 3) | 10.00 | CS/NM | A*01 A*30 DRB1*04 DRB1*11 | 1+ | CR/M (39) |
| PR11 | 73 | G3T3bN0M0 | III | 7 (4 + 3) | 7 (4 + 3) | 18.85 | CS/NM | A*02 A*32 DRB1*04 DRB1*07 | 2+ | NP |
| PR12 | 55 | G2T3bN x M1b | IV | 7 (4 + 3) | ---- | >200 | CR/M | A*26 DRB1*11 | 1+ | D (40) |
| PR13 | 78 | G4T3bN x M1b | IV | 10 (5 + 5) | ---- | 52.03 | CS/M | A*02 A*32 DRB1*04 | 3+ | D (9) |
| PR14 | 48 | G3T3aN0M0 | II | 6 (3 + 3) | 6 (3 + 3) | 8.50 | CS/NM | A*24 A*33 DRB1*03 DRB1*11 | 1+ | NP |
| PR15 | 72 | G1T1bN0M0 | II | 3 (2 + 1) | ---- | 18.90 | CS/NM | A*24 A*29 DRB1*11 | 2+ | NP |
| PR16 | 64 | T2bN0M0 | II | 4 (2 + 2) | ---- | 13.40 | CS/NM | A*24 A*32 DRB1*11 DRB1*15 | 1+ | NP |
| PR17 | 49 | G4T3bN1M1b | IV | 9 (4 + 5) | ---- | 12.00 | CR/M | A*01 DRB1*11 DRB1*13 | 1+ | D (20) |
| PR18 | 57 | G4T3aN x M1b | IV | 9 (4 + 5) | ---- | 1000 | CR/M | A*26 A*32 DRB1*01 DRB1*13 | 1+ | D (21) |
| PR19 | 44 | G2T3bN1M1b | IV | 6 (3 + 3) | ---- | 130.00 | CR/M | A*02 A*24 DRB1*01 DRB1*09 | 2+ | D (13) |
| PR20 | 70 | G3T2aN0M0 | II | 8 (4 + 4) | 7 (3 + 4) | 7.11 | CS/NM | A*02 A*03 DRB1*04 DRB1*12 | 2+ | NP |
| PR21 | 56 | G2T2aN0M0 | III | 8 (4 + 4) | 8 (4 + 4) | 9.50 | CS/NM | A*02 A*03 DRB1*15 DRB1*16 | 1+ | NP |
| PR22 | 63 | G2T3bN0M0 | III | 6 (3 + 3) | 8 (3 + 5) | 6.80 | CS/NM | A*02 A*30 DRB1*15 | 1+ | NP |
| PR23 | 63 | G3T2bN0M0 | II | 7 (3 + 4) | ---- | 97.00 | CS/NM | A*02 A*11 DRB1*04 DRB1*16 | 3+ | LFW (12) |
| PR24 | 81 | G2T2aN0M0 | III | 6 (3 + 3) | ---- | 10.00 | CS/NM | A*01 A*03 DRB1*11 DRB1*16 | 2+ | NP |
| PR25 | 75 | G3T2aN0M0 | II | 8 (3 + 5) | ---- | 7.23 | CR/NM | A*24 A*32 DRB1*04 DRB1*11 | 3+ | NP |
| PR26 | 61 | G4T3aN x M1b | IV | 8 (3 + 5) | ---- | 419.83 | CS/M | A*03 A*11 DRB1*01 DRB1*16 | 2+ | CR/M(45) |
| PR27 | 63 | G4T2bN0M0 | III | 7 (4 + 3) | 8 (4 + 4) | 6.80 | CS/NM | A*02 A*03 DRB1*11 DRB1*15 | 3+ | NP |
| PR28 | 62 | G3T3bN0M0 | III | 8 (3 + 5) | 8 (4 + 4) | 22.98 | CS/NM | A*02 A*24 DRB1*16 | 3+ | NP |
| PR29 | 67 | G2T3bN0M0 | III | 6 (3 + 3) | 10 (5 + 5) | 7.50 | CS/NM | A*03 A*24 DRB1*11 DRB1*13 | 1+ | NP |
| PR30 | 66 | G2T2bN0M0 | III | 6 (3 + 3) | 6 (3 + 3) | 6.00 | CS/NM | A*24 DRB1*03 DRB1*11 | 2+ | NP |
| PR31 | 52 | G3T3bN0M0 | III | 8 (4 + 4) | 8 (5 + 3) | 6.80 | CS/NM | A*02 A*24 DRB1*01 DRB1*11 | 2+ | NP |
| PR32 | 65 | G3T3bN x M1b | IV | 9 (5 + 4) | ---- | 320.00 | CR/M | A*24 A*32 DRB1*07 DRB1*10 | 1+ | NP |
NP no progression, M metastatic, NM non metastatic, CS castrate sensitive, CR castrate resistant, D death, LFW lost in follow-up
*Clinical status by May 2014. Numbers in parentheses represent months from 1st vaccine to change in clinical status